| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faac2981ca475c23cd01c42034521bad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_204ea9f0f83d1c51a916e46a41a6a14a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94e9b240440842bf91199557f5b03e83 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D241-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-498
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate |
2015-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd5c755a00746ee71d96a07b29e0146e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a12e17196ab2384eb8c2ee7b11bcd7c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a4cbc5c40e7e3d5808eac2827ea2252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9898425f76aaae23091a286b2a90b08a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d37d445f0bcdd846f519bc77b06e253
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e59bd08bc04b42162c9d3c0d43d8651
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e18db54d15c8c3c5a3784e465216edf0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87ee2ebb6fee1c0c516cf9361ae63627 |
| publicationDate |
2018-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9969699-B2 |
| titleOfInvention |
Cancer cell growth inhibitor, anticancer agent, and method for screening same, as well as novel compound |
| abstract |
A cancer cell proliferation inhibitor including at least one selected from compounds represented by Structural Formulae (1) to (8), wherein the cancer cell is at least one of a cancer cell overexpressing a wild-type epidermal growth factor receptor and a cancer cell expressing an epidermal growth factor receptor mutant vIII. |
| priorityDate |
2014-09-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |